MabSpace's Second-Gen PD-L1 Candidate Approved for US Trial

Suzhou 's MabSpace Biosciences reports its lead candidate, MSB2311, a second-gen PD-L1 candidate, has been approved to start US clinical trials. The company plans a first-in-human study of MSB2311 in patients with locally advanced or metastatic solid tumors. MabSpace filed for China IND approval of the molecule in October 2017. With its proprietary drug discovery program, MabSpace has formed several partnerships with other China-connected novel drug developers, though it continues to hold worldwide rights to MSB2311. More details.... Share this with colleagues: // //